Effect of terlipressin on renal outcomes in patients with liver cirrhosis and ascites: a retrospective multicenter study.

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Review of Clinical Pharmacology Pub Date : 2026-06-01 Epub Date: 2026-06-21 DOI:10.1080/17512433.2026.2679596

Yong He, Xianxian Zhang, Ting Wang, Xiaohui Fang, Na Sun, Jian Zhang, Yibing Li, Frank Tacke, Wenxiu Zhang, Yanhong Gao, Han Chen, Yunhai Wu, Lichun Shao, Xingshun Qi

{"title":"Effect of terlipressin on renal outcomes in patients with liver cirrhosis and ascites: a retrospective multicenter study.","authors":"Yong He, Xianxian Zhang, Ting Wang, Xiaohui Fang, Na Sun, Jian Zhang, Yibing Li, Frank Tacke, Wenxiu Zhang, Yanhong Gao, Han Chen, Yunhai Wu, Lichun Shao, Xingshun Qi","doi":"10.1080/17512433.2026.2679596","DOIUrl":null,"url":null,"abstract":"Background: Terlipressin is recommended for acute kidney injury (AKI) in cirrhosis, but its role in those with ascites but without AKI is unclear.Methods: We retrospectively enrolled 905 cirrhotic patients with ascites from three hospitals, of whom 250 received terlipressin and 655 standard medical therapy. Patients were stratified by baseline serum creatinine (Scr) into stable renal function (Scr < 133 μmol/L; n = 784) and renal dysfunction (Scr ≥ 133 μmol/L; n = 121) cohorts. Primary outcomes included AKI, renal dysfunction, and renal function improvement. Propensity score matching (PSM) was performed. Multivariable logistic regression was further performed in the stable renal function cohort to assess the independent association between terlipressin and AKI. Odds ratio (OR) was calculated.Results: In the stable renal function cohort, after PSM (n = 120), terlipressin group had lower incidence of AKI (1.67% vs. 16.67%, p = 0.004) and renal dysfunction (0% vs. 8.33%, p = 0.068); and multivariate logistic regression analysis confirmed that terlipressin was independently associated with lower incidence of AKI (OR = 0.093, p = 0.027). In the renal dysfunction cohort, after PSM (n = 34), terlipressin was associated with higher incidence of renal function improvement (70.59% vs. 23.53%, p = 0.006).Conclusion: Terlipressin may be associated with favorable renal outcomes in cirrhotic patients with ascites, regardless of baseline renal function.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"601-613"},"PeriodicalIF":3.6000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17512433.2026.2679596","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Terlipressin is recommended for acute kidney injury (AKI) in cirrhosis, but its role in those with ascites but without AKI is unclear.

Methods: We retrospectively enrolled 905 cirrhotic patients with ascites from three hospitals, of whom 250 received terlipressin and 655 standard medical therapy. Patients were stratified by baseline serum creatinine (Scr) into stable renal function (Scr < 133 μmol/L; n = 784) and renal dysfunction (Scr ≥ 133 μmol/L; n = 121) cohorts. Primary outcomes included AKI, renal dysfunction, and renal function improvement. Propensity score matching (PSM) was performed. Multivariable logistic regression was further performed in the stable renal function cohort to assess the independent association between terlipressin and AKI. Odds ratio (OR) was calculated.

Results: In the stable renal function cohort, after PSM (n = 120), terlipressin group had lower incidence of AKI (1.67% vs. 16.67%, p = 0.004) and renal dysfunction (0% vs. 8.33%, p = 0.068); and multivariate logistic regression analysis confirmed that terlipressin was independently associated with lower incidence of AKI (OR = 0.093, p = 0.027). In the renal dysfunction cohort, after PSM (n = 34), terlipressin was associated with higher incidence of renal function improvement (70.59% vs. 23.53%, p = 0.006).

Conclusion: Terlipressin may be associated with favorable renal outcomes in cirrhotic patients with ascites, regardless of baseline renal function.

查看原文本刊更多论文

特利加压素对肝硬化和腹水患者肾脏预后的影响：一项回顾性多中心研究。

背景：特立加压素被推荐用于肝硬化患者的急性肾损伤（AKI）治疗，但其在腹水但无AKI患者中的作用尚不清楚。方法：我们回顾性纳入来自三家医院的905例肝硬化腹水患者，其中250例接受特利加压素治疗，655例接受标准药物治疗。根据基线血清肌酐（Scr）将患者分为肾功能稳定组(Scr结果：在肾功能稳定组中，PSM （n = 120）后，特利加压素组AKI发生率（1.67% vs. 16.67%, p = 0.001）和肾功能不全发生率（0% vs. 8.33%, p = 0.068）较低；多因素logistic回归分析证实特利加压素与AKI发生率降低独立相关（OR =0.093, p = 0.027）。在肾功能不全队列中，PSM （n = 34）后，特利加压素与肾功能改善发生率较高相关（70.59% vs. 23.53%, p = 0.006）。结论：特利加压素可能与肝硬化腹水患者良好的肾脏预后相关，无论基线肾功能如何。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.30

自引率

2.30%

发文量

127

期刊介绍： Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.